Table 1 Clinical and pathological characteristics of patients in the RESPECT and trans-RESPECT cohorts
RESPECT | Trans-RESPECT | |||||
|---|---|---|---|---|---|---|
All patients | All patients | H arm | H + CT arm | HER2DX low-risk | HER2DX high-risk | |
N | 266 | 154 | 74 | 80 | 114 | 40 |
Mean age | 73.9 | 73.7 | 73.6 | 73.9 | 73.6 | 74.3 |
ER+ disease | 47.7% | 44.2% | 41.9% | 46.3% | 46.5% | 37.5% |
pT stage | ||||||
pT 1 | 48.9% | 51.3% | 52.7% | 50.0% | 61.4% | 22.5% |
pT1b | 16.2% | 19.0% | 15.4% | 22.5% | 21.4% | 0.0% |
pT1c | 83.8% | 81.0% | 84.6% | 77.5% | 78.6% | 100.0% |
pT 2–3 | 51.1% | 48.7% | 47.3% | 50.0% | 38.6% | 77.5% |
pT2 | 94.1% | 92.0% | 85.7% | 97.5% | 90.9% | 93.5% |
pT3 | 5.9% | 8.0% | 14.3% | 2.5% | 9.1% | 6.5% |
pN stage | ||||||
pN 0 | 80.5% | 83.8% | 90.5% | 77.5% | 96.5% | 47.5% |
pN 1–3 | 17.7% | 16.2% | 9.5% | 22.5% | 3.5% | 52.5% |
Unknown | 1.9% | – | – | – | – | – |
TILs | ||||||
<20% | – | 63.4% | 63.0% | 63.8% | 59.3% | 75.0% |
≥20% | – | 36.6% | 37.0% | 36.2% | 40.7% | 25.0% |
HER2DX pCR score | ||||||
Med/Low | – | 48.7% | 44.6% | 52.5% | 53.5% | 55.0% |
High | – | 51.3% | 55.4% | 47.5% | 46.5% | 45.0% |
HER2DX ERBB2 score | ||||||
Low | – | 20.1% | 20.3% | 20.0% | 12.5% | 22.8% |
Med | – | 20.8% | 23.0% | 18.8% | 15.0% | 22.8% |
High | – | 59.1% | 56.7% | 61.2% | 72.5% | 54.4% |